U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
Alnylam Pharmaceuticals (NASDAQ:ALNY) Inc. stock reached an all-time high of 326.12 USD, marking a significant milestone for the $42.45 billion biotechnology company. According to InvestingPro analysis, the stock appears slightly overvalued at current levels, with technical indicators suggesting overbought conditions. Over the past year, the stock has experienced a robust increase, with a 1-year change of 33.54%. The company’s strong momentum is supported by impressive 17.21% revenue growth and a healthy current ratio of 3.04. This upward trajectory reflects growing investor confidence and positive market sentiment towards Alnylam’s innovative therapies and strategic initiatives. InvestingPro subscribers can access 10+ additional insights and a comprehensive Pro Research Report for deeper analysis. The company’s strong performance in the stock market underscores its position as a leader in the RNAi therapeutics space, as it continues to advance its pipeline and commercialize its products. With an overall Financial Health score of "GOOD" from InvestingPro, analysts expect the company to achieve profitability this year.
In other recent news, Alnylam Pharmaceuticals has reported significant developments regarding its RNAi therapeutic, AMVUTTRA. The European Commission has approved AMVUTTRA for treating adult patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), marking the first EC approval of an RNAi therapy for this condition. This approval is supported by data from the HELIOS-B Phase 3 study, which showed notable reductions in mortality and cardiovascular events. Additionally, Alnylam reiterated its 2025 total product revenue guidance of $2.05-2.25 billion during a recent meeting with Needham, which raised its price target for Alnylam to $377.00, maintaining a Buy rating based on optimism about AMVUTTRA’s prospects.
RBC Capital also maintained its Outperform rating and $330.00 price target, citing positive survey data on AMVUTTRA’s market performance. The survey indicated that a significant number of U.S. cardiologists have already prescribed the drug, with minimal payer resistance. In personnel news, Alnylam appointed Pushkal Garg as Executive Vice President, Chief Research and Development Officer, to lead a newly integrated R&D organization. This restructuring aims to accelerate pipeline progress and enhance decision-making. Meanwhile, former Alnylam CEO John Maraganore has joined the board of Axion Bio, a subsidiary of Instil Bio, focusing on advancing cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.